OptiBiotix Health Plc

OPTI

GB00BP0RTP38

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 08:30:39 23/05/2024 BST			5-day change	1st Jan Change
18.01 ^GBX	-0.63%		+0.06%	-32.67%

04-30	EARNINGS AND TRADING: Card Factory profit climbs; Pebble "consistent"	AN
03-25	OptiBiotix Health raises GBP1.4 million to invest in "driving sales"	AN

OptiBiotix appoints CEO Stephen O'Hara as CEO of subsidiary

February 21, 2023 at 02:16 pm

(Alliance News) - OptiBiotix Health PLC on Tuesday said that Rene Kamminga, Chief Executive Officer of subsidiary OptiBiotix Ltd, will leave the business next week Tuesday.

The York, England-based probiotics developer tackling obesity, cardiovascular diseases and lifestyle conditions announced it appointed its CEO Stephen O'Hara as CEO of the subsidiary.

O'Hara "will lead a minor restructuring of the business," OptiBiotix added.

Optibiotix shares were 2.8% lower at 12.89 pence each in London on Tuesday afternoon.

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about OptiBiotix Health Plc

EARNINGS AND TRADING: Card Factory profit climbs; Pebble "consistent"	04-30	AN
OptiBiotix Health raises GBP1.4 million to invest in "driving sales"	03-25	AN
OptiBiotix Health Raises GBP1.4 Million via Share Placing, Subscription	03-25	MT
EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal	03-13	AN
OptiBiotix Health plc Signs Partnership Agreement with Dr Morepen Ltd	03-13	CI
OptiBiotix products return to sales growth as pipeline strong	02-27	AN
OptiBiotix in discussions for launch of SweetBiotix	01-30	AN
OptiBiotix Health to Launch Sports Nutrition Product in Europe	01-15	MT
OptiBiotix's LeanBiome to be launched under MuscleTech	01-15	AN
OptiBiotix Health PlcAnnounces Launch of LeanBiome in Muscletech	01-15	CI
OptiBiotix names Croda's Graham Myers as finance director	12-04	AN
UK's Optibiotix Health Appoints Finance Director	12-04	MT
Optibiotix Health plc Appoints Graham Myers as Finance Director	12-04	CI
Scancell trial progresses; OptiBiotix inks new deal	11-28	AN
Optibiotix Health plc Signs an Agreement with Ravenswood Ingredients Pty Ltd ("Ravenswood") for the Distribution of Slimbiome®In Australia and New Zealand	11-28	CI
EARNINGS AND TRADING: Victorian Plumbing profit up; Duke revenue dips	11-22	AN
OptiBiotix says market still "volatile" but partner sales improving	11-01	AN
OptiBiotix Health Expands Network in US, Asia	11-01	MT
OptiBiotix Health Secures License Deal for Tata Chemicals' Fossence; Shares Jump	23/10/23	MT
OptiBiotix adds Tata Chemicals ingredient to obesity product in India	23/10/23	AN
EARNINGS: Safestyle suffers amid "difficult" trading conditions	27/09/23	AN
Earnings Flash (OPTI.L) OPTIBIOTIX HEALTH Posts H1 Revenue GBP351,000	27/09/23	MT
Earnings Flash (OPTI.L) OPTIBIOTIX HEALTH Reports H1 Loss GBX-2.09	27/09/23	MT
OptiBiotix Health Plc Reports Earnings Results for the Half Year Ended June 30, 2023	27/09/23	CI
OptiBiotix Health to Launch Three Products in FY24; Shares Jump 18%	22/09/23	MT

OptiBiotix Health Plc is a United Kingdom-based life sciences company. The Company is primarily engaged in identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry segment. Its technology platforms include OcptiBiome, OptiScreen and OptiBiotic. Its OptiBiome technology platform that screens identifies and/or develops microbiome modulators, which can be used in formulations to prevent, manage and a range of chronic lifestyle diseases. The OptiScreen pharmaceutical screening platform to identify microbial metabolic pathways that interact with human pathways to improve health. The OptiBiotic platform generates oligosaccharides and screens them for their ability to modulate specific microbial genera or species and their microbial end products (short chain fatty acids, such as acetate, propionate, butyrate) and physical properties (sweetness). Its products include SlimBiome, SweetBiotix, CholBiomeX3, SlimBiome Medical and WellBiome.

Sector

Biotechnology & Medical Research

Calendar

25/06/2024 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OPTIBIOTIX HEALTH PLC	-32.67%	22.59M
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-1.11%	21.97B
GENMAB A/S	-5.34%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B

Bio Therapeutic Drugs

OptiBiotix Health Plc

Equities

OPTI

GB00BP0RTP38

Biotechnology & Medical Research

OptiBiotix appoints CEO Stephen O'Hara as CEO of subsidiary

Latest news about OptiBiotix Health Plc

Chart OptiBiotix Health Plc

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs